Shire plc Shire Plc : Directorate Change

TIDMSHP 
 
 
   Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member 
of the Board of Directors 
 
   November 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global 
biotech leader in rare diseases, today announced that Thomas Dittrich 
will join the company as Chief Financial Officer, and become an 
Executive member of the Board of Directors and a member of the Executive 
Committee. Thomas will assume his roles at Shire in early 2018 following 
a transition period from his current employer. 
 
   "Thomas's wealth of experience while leading the finance teams at 
numerous multinational companies, including Amgen for several years, 
will be a tremendous asset for Shire as we continue to execute as the 
leading global biotech focused on rare diseases," said Dr.  Flemming 
Ornskov, MD, MPH, Chief Executive Officer, Shire. "His unique financial 
skillset and results-oriented mentality make him the right person to 
lead Shire's finance function." 
 
   Thomas is currently Chief Financial Officer and a member of the 
Executive Committee at Sulzer Ltd, a publicly-listed, global industrial 
engineering and manufacturing company. He joined Sulzer in August 2014, 
serving as Chief Executive Officer ad interim between August 2015 and 
December 2015. At Sulzer, he was instrumental in designing the company's 
transformation program and drove key upgrades to finance and IT 
functions, as well as to capital structure and resource allocation 
initiatives. 
 
   Prior to joining Sulzer, Thomas served as Vice President, Finance 
Corporate Planning and Chief Accounting Officer of Amgen Inc. between 
2010 and 2014. Between 2006 and 2010, he was Vice President, Finance and 
Chief Financial Officer of Amgen International. Thomas also spent eight 
years with Dell where he held various finance and general manager roles. 
Earlier in his career, Thomas worked at Booz & Co and Helbing Management 
Consulting AG in operational and merger and acquisition roles, 
respectively. 
 
   "Thomas is a talented global executive who will bring to Shire a broad 
range of experiences from both inside and outside the pharmaceutical 
industry," said Susan Kilsby, Chairman of the Board at Shire. "The Board 
and I look forward to working with him during this transformational time 
in the Company's history." 
 
   "I am thrilled to join Shire at such an exciting time in the Company's 
evolution," said Thomas Dittrich. "I look forward to working with the 
Board, the Executive Committee and the Finance organization as we build 
upon Shire's strong fundamentals to drive future growth and shareholder 
value." 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Ian Karp             [e-mail]      [phone] 
Robert Coates        [e-mail]   [phone] 
 
  Media 
Amy Ryan             [e-mail]     [phone] 
Katie Joyce          [e-mail]     [phone] 
 
 
   NOTES TO EDITORS 
 
   No further information is required to be disclosed pursuant to 9.6.13R 
of the UK Listing Rules. 
 
   About Shire 
 
   Shire is the leading global biotechnology company focused on serving 
people with rare diseases. We strive to develop best-in-class products, 
many of which are available in more than 100 countries, across core 
therapeutic areas including Immunology, Hereditary Angioedema, 
Hematology, Lysosomal Storage Disorders, Gastrointestinal / Internal 
Medicine / Endocrine, Ophthalmics, a growing franchise in Oncology, and 
Neuroscience. 
 
   Our employees come to work every day with a shared mission: to develop 
and deliver breakthrough therapies for the hundreds of millions of 
people in the world affected by rare diseases and other high-need 
conditions, and who lack effective therapies to live their lives to the 
fullest. 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire 
 
 
 
 

(END) Dow Jones Newswires

November 20, 2017 08:15 ET (13:15 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.